Table 1.
Pretreatment characteristics of the study population of 42 patients with CML.
| Variable | no. |
|---|---|
| Gender, n. (%) | |
| Male | 26 |
| Female | 16 |
| Age (yrs) (median range) | 40 (16–69) |
| Time from diagnosis (yr) (median range) | 1.5 (0.1–7) |
| ECOG at diagnosis | |
| 0-1 | 25 (59) |
| 2-3 | 17 (41) |
| Hepatomegaly n (%) | 15 (36) |
| Splenomegaly, n (%) | |
| 0 cm | 4 (10) |
| 1–9 cm bcma | 25 (59) |
| ≥10 cm bcm | 13 (31) |
| Peripheral blood (median range) | |
| Hemoglobin level (g/dL) | 10.2 (5.7–13.7) |
| Platelet count (109/L) | 331.5 (132–1992) |
| Leukocyte count (109/L) | 211.7 (50–854) |
| Basophils in PB (%) | 0 (0–6) |
| Blasts in PB (%) | 1.9 (1–8) |
| Blasts in BM (%) | 1 (0–4) |
| Ph status before therapy, n (%) | |
| Ph1+ | 25 (59) |
| Additional chromosomal abnormalities | 17 (41) |
| Sokal score | |
| Low risk. n. (%) | 11 (16.6) |
| Intermediate risk n. (%) | 16 (44.5) |
| High risk n. (%) | 15 (38.9) |
Cma: centimeters below the costal margin.